Illinois Medical Studies Act Requires Hospital to Disclose Number of MRSA Infections
Medical Litigation Alert
Healthcare Alert | 1 min read
Sep 21, 2011
In Zangara v. Advocate Christ Medical Center and Dziamara v. Advocate Christ Medical Center, (consolidated for appeal), the Illinois Appellate Court, First District, considered the implications of the Illinois Medical Studies Act concerning certain infection control information at defendant hospital. Plaintiffs appealed the trial court’s rulings dismissing their actions for failure to comply with 735 ILCS 5/2-622, which requires the filing of a physician’s report stating that the medical malpractice suit sets forth a meritorious cause of action.
Plaintiffs in the cases each argued that they were prevented from filing a report because of the hospital’s refusal to provide them with information regarding the frequency of methicillin-resistant staphylococcus aureus (MRSA) infections at the hospital facility. The hospital argued that collection of the number of MRSA infections was information protected from discovery by the Illinois Medical Studies Act (IMSA) as data used for purposes of internal quality control and improving patient care. The appellate court disagreed, finding that the infection data would be generated in the course of the hospital’s business and any later submission to a committee for quality-assurance purposes would not render it protected. On remand, the facility was ordered to determine and communicate the number of MRSA infections at the facility during the pertinent timeframe.Zangara v. Advocate Christ Medical Center; Paul Gordon; Ajay Parikh; and Sunil Shah, 1-09-1911 (1st Dist. 2011); Dziamara v. Advocate Christ Medical Center, and Illinois Corporation a/k/a Advocate Health and Hospitals Corporation, Manor Care of Palos Heights, 1-09-1914 (1st Dist. 2011). The appellate court's ruling appears to label the collection of infection information in-house as efforts made in the “regular course of business” and therefore not protected from discovery by the IMSA.
For further information, please contact your regular Hinshaw attorney.
This alert has been prepared by Hinshaw & Culbertson LLP to provide information on recent legal developments of interest to our readers. It is not intended to provide legal advice for a specific situation or to create an attorney-client relationship.
Featured Insights

In The News
Nov 17, 2026
Justin Penn Examines FCRA Trends Involving “Legal vs. Factual Inaccuracy” Defense

Consumer Crossroads: Where Financial Services and Litigation Intersect
Nov 16, 2026
SCOTUS to Decide: Are Bankruptcy Stay Violations Arbitrable?

Press Release
Nov 13, 2026
Hinshaw Advises Client Safe Harbor Capital Partners in $44 Million Financing

In The News
Nov 12, 2026
Spencer Kook Authors Article Providing a Claims Manager’s Guide to Class Action Exposure

In The News
Nov 12, 2026
Mitch Chargo Discusses Cannabis M&A Implications in a Post-Rescheduling Landscape

Webinar
Nov 12, 2026
Michael Adams Presents on Navigating Ethics in the Digital Age

Event
Nov 12, 2026
Cathy Mulrow-Peattie Discusses AI and Supply Chain Cybersecurity

Healthcare Alert
Nov 11, 2026
Illinois Enacts 340B Contract Pharmacy Protections: 7 Steps Covered Entities Should Take

In The News
Nov 10, 2026
Brian Turetsky Examines How NYC’s Proposed POWER Act Could Expand Private UDAAP Claims

In The News
Nov 9, 2026
Kate Schnake Examines Unlawful Discrimination vs. Legitimate Advocacy in Jury Selection

Press Release
Nov 6, 2026
Hinshaw Recognized by the LCLD as a 2026 Compass Award Winner and Top Performer

